Table 3 Cervical cancer-related readiness index scores by facility type (n = 126)
Services for cervical cancer | Upazila health complex, n (%) | Union-level public facilities, n (%) | Community clinic, n (%) | Private facilities, n (%) | Totaln (%) | P-value |
|---|---|---|---|---|---|---|
Overall | 9 (7.1) | 36 (28.6) | 53 (42.1) | 28 (22.2) | 126 (100) | Â |
Staff and guidelines | ||||||
 Guidelines on the diagnosis and treatment of cervical cancer | 0 | 0 | 0 | 0 | 0 |  |
 At least one trained staff member (within 24 months) | 2 (22.2) | 0 | 0 | 1 (3.6) | 3 (2.4) |  |
Mean (± SD) | 11.1 (± 15.7) | N/A | N/A | 1.8 (± 2.5) | 1.2 (± 1.7) | 0.545 |
Basic equipment | ||||||
 Speculum | 9 (100) | 24 (66.7) | 0 | 15 (53.6) | 48 (38.1) |  |
Mean (± SD) | N/A | N/A | N/A | N/A | N/A | N/A |
Diagnostic facility | ||||||
 Acetic Acid | 4 (44.4) | 0 | 0 | 6 (21.4) | 10 (7.9) |  |
 Cytology | 0 | 0 | 0 | 3 (10.7) | 3 (2.4) |  |
 Cancer antigen 15.3 (CA 15.3) | 0 | 0 | 0 | 0 | 0 |  |
 Cancer antigen 125 (CA125) | 0 | 0 | 0 | 0 | 0 |  |
 Colposcopy | 0 | 0 | 0 | 0 | 0 |  |
Mean (± SD) | 5.6 (15.7) | N/A | N/A | 4.0 (± 8.0) | 1.3 (± 2.8) | 0.537 |
Essential medicines | ||||||
 Hydrocortisone | 0 | 0 | 0 | 0 | 0 |  |
 Lorazepam | 0 | 0 | 0 | 0 | 0 |  |
 Morphin | 0 | 0 | 0 | 0 | 0 |  |
 Ondanseron | 0 | 0 | 0 | 0 | 0 |  |
 Pheniramine | 0 | 0 | 0 | 0 | 0 |  |
 Broad Spectrum Antibiotics | 0 | 0 | 0 | 0 | 0 |  |
Mean (± SD) | N/A | N/A | N/A | N/A | N/A | N/A |